Andrew P. Han
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
AI and lab automation were some of the strategic efforts Ginkgo officials noted as the firm missed analysts' estimates on the top and bottom lines for Q4 and 2023.
In a preprint posted earlier this month, the team behind the UK-based firm described its assay for targeting unmethylated CpG sites in the human genome.
A trio of companies is planning to offer single-cell DNA sequencing assays with the ability to do transcriptomics and other modalities.
At last week's AGBT meeting, the companies showcased new chemistries that turn their flow cells into stages for RNA, protein, and cellular analysis.
The new chip, presented at AGBT among other updates, should double the number of cells per channel while improving sensitivity and recovery, among other benefits.
At the annual AGBT General Meeting, early Ultima customers shared their experiences using the new instrument to satisfy their most sequencing-intensive applications.
Frustrations with spatial tissue profiling technologies have prompted researchers from around the world to band together and get everyone on the same page.
The program will provide funding and expertise to clinics in low-income countries to run methylation array-based assays to classify central nervous system tumors in children.
Personal Genomics's CEO said the firm is considering adding claims that PacBio's new Revio sequencer also infringes its patent.
The sequencing instrument maker plans to double its installed base from about 112 at the end of 2023 and plans several new technology releases this year.